Pomegra
Albert Invent has raised $55 million in a TCV-led Series B, reportedly at a $340 million valuation, to expand its chemistry-specific AI platform for R&D.
Key Takeaways
- Albert Invent closed a $55M Series B on October 13, 2026, led by TCV.
- Forbes reported a $340M valuation; the company has not confirmed it.
- Coatue, J.P. Morgan Growth Equity Partners, Index Ventures and Applied Ventures returned.
Lead
Albert Invent, the Oakland-based maker of a chemistry-native AI operating system for R&D, announced a $55 million Series B on October 13, 2026. TCV led the round. New investors Delta-v Capital, Socium Ventures, HighSage Ventures, Coral Capital and Legion VC joined, alongside existing backers Coatue, J.P. Morgan Growth Equity Partners, Index Ventures and Applied Ventures. Forbes reported the valuation at about $340 million. The company has not disclosed a figure.
What Does Albert Invent Actually Sell?
Albert sells Albert OS, a software layer that sits over a chemical company's experiments, formulations and data. Its in-house model, Valence, was trained on 15 million molecular structures and the chemical patent corpus. The company says Valence is 45 times more accurate on scientific queries than general-purpose AI.
The platform also includes Ask Albert, a natural-language assistant that coordinates tools, agents and models. The company published FormBench, a benchmark for AI in formulation chemistry. Since Albert wrote the benchmark and also sits at the top of it, the 45x figure is best read as a vendor claim until outside labs reproduce it.
Customers named by the company include AkzoNobel, Avient, BASF, Chemours, Clorox, Henkel, Kenvue and Nouryon. These are large formulators, which is the company's target market. They also buy slowly and carry heavy data-governance requirements.
How Fast Is the Company Growing?
Usage figures are strong but come with no revenue number. Year over year, project creation grew 26 times, the number of scientists on the platform rose six times across 44 countries, and workflow creation grew fourfold. Albert did not disclose revenue, contract values or retention.
Usage growth from a small base can look dramatic. A 26x jump in projects shows adoption inside existing accounts, but it does not show how much customers pay for it. CEO and co-founder Nick Talken, a former head of digital R&D at Henkel who started the company in 2022, told Forbes that 30 percent of scientific experiments are duplicative and wasteful. That claim is the economic case for the product: cut repeat experiments and shorten development cycles.
What Does the Round Imply About Earlier Funding?
The round shows investors are adding to a thesis they already held. Albert disclosed a $22 million Series A led by Coatue, with Index, TCV, F-Prime and Homebrew participating. A growth round led by J.P. Morgan's private capital arm followed in February 2025, with an undisclosed amount, taking total funding to more than $45 million. The Series B brings the disclosed total to roughly $100 million.
TCV appeared in the earlier rounds and now leads. Coatue and J.P. Morgan Growth Equity Partners stayed in. A lead that already knows the company and its pipeline usually pays a lower information premium. It also suggests the earlier rounds did not turn up problems that would have put off existing investors.
TCV partner Morgan Gerlak described the problem the company targets: "R&D in chemistry still runs largely on spreadsheets and institutional memory."
Why Does Chemistry Draw Specialized AI Rather Than General Models?
Chemistry draws specialized AI because formulation work depends on proprietary data that general models have not seen. Formulations combine dozens of ingredients, and the results depend on processing conditions, supplier variation and decades of internal lab notes. General-purpose models trained on public text handle that poorly.
Albert's pitch is that a purpose-built model plus a governed data layer solves this. The company lists zero data retention, fine-grained access controls and reasoning audit trails. Those features matter to formulators who treat recipes as trade secrets, and they are a reason some customers would favor a vertical vendor over a general model provider.
What Comes Next?
The funds will go toward expanding Albert's chemistry-native AI capabilities and shortening customers' development cycles, according to the company. The harder test is competitive. Large chemical groups run internal data science teams, and general model providers are courting the same R&D budgets. Albert has to show that its accuracy edge survives independent testing and that large accounts expand spending beyond pilots.
If the reported $340 million valuation holds, the round values the company at roughly six times the new capital. That is a modest multiple for an AI platform company, and it leaves room for a larger round if revenue figures back up the usage growth.
Outlook
Albert Invent has about $100 million in disclosed funding, a lead investor that already knew the company, and usage growth that outpaces what it has disclosed about revenue. The next milestones are independent validation of Valence, customer expansion at the major formulators already on the platform, and some public indication of revenue. Until those arrive, the round is a bet on vertical AI in a data-rich, slow-moving industry.
